Adamas Pharmaceuticals | Advantaged Therapeutics

	Contact \|

Overview Management Team Board of Directors Scientific & Clinical Advisors Investors Contact Us

Our Approach Diseases Clinical Trials Commercialization Partners

Publications & Presentations Reference Library

Press Releases Media Coverage Events

Culture Benefits Job Postings

TRINITY is setting the industry gold standard for oral delivery of macromolecules.

	A New Model In Advantaged Therapeutics Read More
	About TCAD Read More TCAD
	CNS Programs Parkinson's Disease Dementia

News

In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses ť

Adamas Pharmaceuticals Expands Clinical Study For Triple-Combination Antiviral Drug Therapy In Immunocompromised
Patients ť

Adamas Pharmaceuticals Raises $40 Million in Series D Financing ť

Adamas is focused on developing small molecule, Advantaged Therapeutics to treat neurological and infectious diseases, including Influenza A/H1N1, the cause of the current flu pandemic.